- Achieved lowest operating loss in ten years of DKK 161 million
- Increased cash in 2010 by DKK 265 million to DKK 1,546 million
- Lowered operating expenses to DKK 743 million, beating previous guidance, further reductions guided in 2011
- Increase in Arzerra royalties by 48% to a projected DKK 80 million in 2011
In order to read Genmab’s Financial Statements Release 2010 please see the attached file.
Contact:
Helle Husted, Vice President, Investor Relations
T: +45 33 44 77 30
M: +45 25 27 47 13
E: h.husted@genmab.com
www.genmab.com
Stock Exchange Release no. 03
CVR no. 2102 3884
Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark
